The Newer Fluoroquinolones

被引：68

作者：

Bolan, Maureen K. ^{[1
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Dept Med, Chicago, IL 60611 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 04期

关键词：

Fluoroquinolones; Antiinfective agents; Pharmacology; Pharmacokinetics; Microbial drug resistance; Therapeutic use; RESISTANT STAPHYLOCOCCUS-AUREUS; DIFFICILE-ASSOCIATED-DIARRHEA; INTENSIVE-CARE UNITS; STREPTOCOCCUS-PNEUMONIAE; CLOSTRIDIUM-DIFFICILE; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; QUINOLONE-RESISTANCE; TOPOISOMERASE-IV; HONG-KONG;

D O I：

10.1016/j.idc.2009.06.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Clinicians have enthusiastically used fluoroquinolones owing to their good safety profile and wide range of indications. This article reviews fluoroquinolone pharmacology, pharmacodynamic principles, and fluoroquinolone resistance mechanisms, highlighting recent trends in the epidemiology of fluoroquinolone resistance among gram-negative organisms and Streptococcus pneumonia. Important fluoroquinolone safety concerns are discussed, along with indications for the most commonly used fluoroquinolones ciprofloxacin, levofloxacin, and moxifloxacin.

引用

页码：1027 / +

页数：26

共 93 条

[1] Torsade de pointes associated with moxifloxacin: A rare but potentially fatal adverse event [J].

Altin, Timucin ;

Ozcan, Ozgur ;

Turhan, Sibel ;

Ozdemir, Aydan Ongun ;

Akyurek, Omer ;

Karaoguz, Remzi ;

Guldal, Muharrem .

CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 (11) :907-908

[2] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].

Ambrose, PG ;

Grasela, DM ;

Grasela, TH ;

Passarell, J ;

Mayer, HB ;

Pierce, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797

[3] The quinolones: Past, present, and future [J].

Andriole, VT .

CLINICAL INFECTIOUS DISEASES, 2005, 41 :S113-S119

[4]

[Anonymous], 2000, QUINOLONES

[5] Adverse drug reactions: implications for the development of fluoroquinolones [J].

Ball, P .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :21-27

[6] High rate of coadministration of di- or tri-valent cation-containing compounds with oral fluoroquinolones: Risk factors and potential implications [J].

Barton, TD ;

Fishman, NO ;

Weiner, MG ;

LaRosa, LA ;

Lautenbach, E .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (01) :93-99

[7] TEMAFLOXACIN SYNDROME - REVIEW OF 95 CASES [J].

BLUM, MD ;

GRAHAM, DJ ;

MCCLOSKEY, CA .

CLINICAL INFECTIOUS DISEASES, 1994, 18 (06) :946-950

[8] Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada [J].

Bozeman, L ;

Burman, W ;

Metchock, B ;

Welch, L ;

Weiner, M .

CLINICAL INFECTIOUS DISEASES, 2005, 40 (03) :386-391

[9] Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae [J].

Brenwald, NP ;

Gill, MJ ;

Wise, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2032-2035

[10] Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia [J].

Bucaneve, G ;

Micozzi, A ;

Menichetti, F ;

Martino, P ;

Dionisi, MS ;

Martinelli, G ;

Allione, B ;

D'Antonio, D ;

Buelli, M ;

Nosari, AM ;

Cilloni, D ;

Zuffa, E ;

Cantaffa, R ;

Specchia, G ;

Amadori, S ;

Fabbiano, F ;

Deliliers, GL ;

Lauria, F ;

Foà, R ;

Del Favero, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (10) :977-987

← 1 2 3 4 5 6 7 8 9 10 →